-
1
المؤلفون: René Westhovens, Kristien Van der Elst, Johan Joly, Veerle Stouten, Annelies Boonen, S. Pazmino, Patrick Verschueren, Diederik De Cock
المساهمون: Public Health Sciences, Interne Geneeskunde, MUMC+: MA Reumatologie (9), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation
المصدر: Annals of the Rheumatic Diseases, 79(5), 556-565. BMJ Publishing Group
مصطلحات موضوعية: Male, Time Factors, Cost effectiveness, Cost-Benefit Analysis, Cobra, Severity of Illness Index, DISEASE, Arthritis, Rheumatoid, 0302 clinical medicine, Antirheumatic Agents/administration & dosage, Immunology and Allergy, Medicine, 030212 general & internal medicine, Range of Motion, Articular, Methotrexate/administration & dosage, Pain Measurement, computer.programming_language, Leflunomide, education.field_of_study, Remission Induction, TREATMENT STRATEGIES, Middle Aged, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Arthritis, Rheumatoid/diagnosis, Drug Therapy, Combination, Female, Quality-Adjusted Life Years, CLINICAL-TRIALS, medicine.drug, Range of Motion, Articular/physiology, medicine.medical_specialty, Immunology, Population, QUESTIONNAIRE, Leflunomide/administration & dosage, Risk Assessment, Statistics, Nonparametric, General Biochemistry, Genetics and Molecular Biology, MULTIPLE IMPUTATION, 03 medical and health sciences, Sulfasalazine/administration & dosage, UTILITIES, Rheumatology, EQ-5D, Internal medicine, Humans, COMBINATION, education, Aged, 030203 arthritis & rheumatology, business.industry, Early rheumatoid arthritis, medicine.disease, Sulfasalazine, Clinical trial, Early Diagnosis, Methotrexate, MODIFYING ANTIRHEUMATIC DRUGS, business, computer, Follow-Up Studies
-
2
المؤلفون: Matthew J. McIntosh, Michaela Koehm, Harald Burkhardt, Varghese Abraham, Michael Hofmann, Frank Behrens, Arthur Kavanaugh, Ernest Choy, Cem Gabay
المصدر: Rheumatology International, Vol. 40, No 5 (2020) pp. 747-755
مصطلحات موضوعية: musculoskeletal diseases, medicine.medical_specialty, Immunology, Logistic regression, Severity of Illness Index, Antibodies, Rheumatoid/drug therapy, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, Antirheumatic Agents/administration & dosage, Rheumatology, Randomized controlled trial, law, Internal medicine, Monoclonal, medicine, Humans, Immunology and Allergy, Patient Reported Outcome Measures, 030212 general & internal medicine, skin and connective tissue diseases, Randomized Controlled Trials as Topic, Retrospective Studies, Tumor Necrosis Factor Inhibitors/administration & dosage, ddc:616, 030203 arthritis & rheumatology, medicine.diagnostic_test, business.industry, Arthritis, Blood Sedimentation/drug effects, medicine.disease, Observational Studies as Topic, Treatment Outcome, chemistry, Rheumatoid arthritis, Erythrocyte sedimentation rate, Humanized/administration & dosage, Observational study, business, Rheumatism
-
3
المؤلفون: An De Groef, Kristien Van der Elst, Johan Joly, Veerle Stouten, S. Pazmino, Philip Moons, Rene Westhovens, Diederik De Cock, Johanna E. Vriezekolk, Patrick Verschueren
المساهمون: Public Health Sciences
المصدر: RMD Open, Vol 6, Iss 1 (2020)
RMD Openمصطلحات موضوعية: Male, Coping (psychology), lcsh:Medicine, Severity of Illness Index, Arthritis, Rheumatoid, 0302 clinical medicine, Antirheumatic Agents/administration & dosage, Immunology and Allergy, Fatigue/drug therapy, 030212 general & internal medicine, Methotrexate/administration & dosage, Pain Measurement, media_common, Middle Aged, Treatment Outcome, Feeling, Arthritis, Rheumatoid/drug therapy, patient-reported outcomes, Antirheumatic Agents, Rheumatoid arthritis, Female, Adult, medicine.medical_specialty, media_common.quotation_subject, Concordance, Immunology, unmet needs, Pain, Rheumatoid Arthritis, Illness perceptions, 03 medical and health sciences, Rheumatology, Pain/drug therapy, Internal medicine, medicine, Humans, Patient Reported Outcome Measures, Aged, 030203 arthritis & rheumatology, business.industry, lcsh:R, Recovery of Function, Early rheumatoid arthritis, medicine.disease, Methotrexate, Recovery of Function/drug effects, Well-being, Quality of Life, fatigue, Observational study, business, cluster analysis
-
4
المؤلفون: Maria C. Cid, Alfred Mahr, Raashid Luqmani, Frank Buttgereit, Bernhard Hellmich, Sara Monti, Carlo Salvarani, Christian Dejaco, Wolfgang A. Schmidt, Cristina Ponte, Ana Filipa Águeda
المساهمون: Repositório da Universidade de Lisboa
المصدر: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
RMD Openمصطلحات موضوعية: Male, Autoimmune diseases, Blindness, Antibodies, Monoclonal, Humanized / administration & dosage, chemistry.chemical_compound, Biomarkers / metabolism, Recurrence, Outcome Assessment, Health Care, Systemic vasculitis, Immunology and Allergy, skin and connective tissue diseases, Giant cell arteritis, Randomized Controlled Trials as Topic, Glucocorticoids / therapeutic use, HSM REUM, Takayasu Arteritis / complications, Blindness / prevention & control, Observational Studies as Topic, Systematic review, Antirheumatic Agents, Giant Cell Arteritis / metabolism, Antirheumatic Agents / administration & dosage, Female, Drug Therapy, Combination, Vasculitis, medicine.medical_specialty, Giant Cell Arteritis / complications, Antibodies, Monoclonal, Humanized / therapeutic use, Immunology, MEDLINE, Methotrexate / therapeutic use, Antibodies, Monoclonal, Humanized, Tocilizumab, Rheumatology, Large vessel vasculitis, medicine, Humans, Intensive care medicine, Adverse effect, Glucocorticoids, Takayasu Arteritis / drug therapy, Risk Management, Systemic Vasculitis / pathology, Giant Cell Arteritis / diagnosis, business.industry, Antirheumatic Agents / therapeutic use, Giant Cell Arteritis / drug therapy, Methotrexate / administration & dosage, Evidence-based medicine, medicine.disease, Takayasu Arteritis, Methotrexate, chemistry, Glucocorticoids / administration & dosage, business, Biomarkers
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd4df5c1851db2ca5c89c154005674de
-
5
المؤلفون: Ib Tønder Hansen, Kristian Stengaard-Pedersen, Julia S. Johansen, Peter Junker, Hanne Merete Lindegaard, Mikkel Østergaard, Torkell Ellingsen, Anette Jørgensen, Merete Lund Hetland, Hans Christian Horn, Sophine B. Krintel, Johnny Lillelund Raun, Mette Yde Dam, Christian Gytz Ammitzbøll, Palle Ahlquist, Annette Schlemmer, Jan Pødenphant, Opera study-group, Asta Linauskas, Kim Hørslev-Petersen
المصدر: Hørslev-Petersen, K, Hetland, M L, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Horn, H C, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Johansen, J S, Ostergaard, M, Stengaard-Pedersen, K & OPERA study-group 2014, ' Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study : An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial ', Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 654-661 . https://doi.org/10.1136/annrheumdis-2012-202735
Hørslev-Petersen, K, Hetland, M L, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Tønder Hansen, I, Horn, H C, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Johansen, J S, Østergaard, M, Stengaard-Pedersen, K & OPERA Study Group 2013, ' Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study : an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/annrheumdis-2012-202735
OPERA Study Group 2014, ' Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life : The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial ', Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 654-661 . https://doi.org/10.1136/annrheumdis-2012-202735مصطلحات موضوعية: Adult, Male, musculoskeletal diseases, medicine.medical_specialty, Triamcinolone acetonide, Immunology, Placebo-controlled study, Antibodies, Monoclonal, Humanized, Triamcinolone, Severity of Illness Index, Drug Administration Schedule, General Biochemistry, Genetics and Molecular Biology, Injections, Intra-Articular, Arthritis, Rheumatoid, Antirheumatic Agents/administration & dosage, Double-Blind Method, Rheumatology, Quality of life, Internal medicine, medicine, Adalimumab, Humans, Immunology and Allergy, Methotrexate/administration & dosage, Aged, business.industry, Remission Induction, Middle Aged, medicine.disease, Connective tissue disease, Surgery, Clinical trial, Methotrexate, Treatment Outcome, Arthritis, Rheumatoid/drug therapy, Antirheumatic Agents, Rheumatoid arthritis, Quality of Life, Triamcinolone/administration & dosage, Drug Therapy, Combination, Female, business, Antibodies, Monoclonal, Humanized/administration & dosage, medicine.drug
-
6
المؤلفون: Madhvi, Menon, Paul A, Blair, David A, Isenberg, Claudia, Mauri
المصدر: Menon, M, Blair, P A, Isenberg, D A & Mauri, C 2016, ' A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus ', Immunity, vol. 44, no. 3, pp. 683-697 . https://doi.org/10.1016/j.immuni.2016.02.012
Immunityمصطلحات موضوعية: STAT3 Transcription Factor, Transcriptional Activation, Adult, Homeostasis/drug effects, Male, Immunology, Cell Communication/drug effects, Antigens, CD/metabolism, Cell Communication, Article, Cell Physiological Phenomena, Rituximab/administration & dosage, Dendritic Cells/drug effects, Interleukin-10/metabolism, Interferon-gamma, Young Adult, Antirheumatic Agents/administration & dosage, Antigens, CD, immune system diseases, Homeostasis, Immunology and Allergy, Lupus Erythematosus, Systemic, Humans, skin and connective tissue diseases, Cells, Cultured, Aged, Interferon-gamma/metabolism, B-Lymphocytes, Regulatory, Cell Differentiation, hemic and immune systems, Dendritic Cells, Middle Aged, Interleukin-10, B-Lymphocytes, Regulatory/drug effects, STAT1 Transcription Factor, Infectious Diseases, STAT3 Transcription Factor/metabolism, Antirheumatic Agents, Cell Differentiation/drug effects, Female, Lupus Erythematosus, Systemic/drug therapy, STAT1 Transcription Factor/metabolism, Transcriptional Activation/drug effects, Rituximab
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6360c924dbe40ed812fed1bc6c4f32df
https://www.research.manchester.ac.uk/portal/en/publications/a-regulatory-feedback-between-plasmacytoid-dendritic-cells-and-regulatory-b-cells-is-aberrant-in-systemic-lupus-erythematosus(1d3ade0f-c5b6-4cc3-b03e-877898151a19).html -
7
المؤلفون: Peter Lamprecht, Thierry Schaeverbeke, Hendrik Schulze-Koops, Eugen Feist, Jürgen Rech, Bernhard Hellmich, Eduardo Schiffrin, Delphine S. Courvoisier, Jacques Morel, Thierry Martin, Eric Hachulla, Bruno Fautrel, Andrew Sleight, Cem Gabay, Ina Kötter, Mohamed Hamidou, François Spertini
المساهمون: Department of Pathology and Immunology [Geneva, Switzerland] (Clinical Pathology Division), University of Geneva [Switzerland]-Geneva University Hospitals - HUG [Switzerland], Division of Rheumatology [Geneva, Switzerland], Geneva University Hospital, Geneva-Department of Internal Medicine [Genève], Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Division of Immunology and Allergy [Lausanne, Suisse], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Department of Internal Medicine II, University of Tübingen, Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Rhumatologie Bordeaux (SERVICE DE RHUMATOLOGIE), CHU Bordeaux [Bordeaux], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire de Génie des Procédés et Matériaux - EA 4038 (LGPM), CentraleSupélec, Degauque, Nicolas, Université de Genève = University of Geneva (UNIGE)-Geneva University Hospitals - HUG [Switzerland], Service de Rhumatologie [CHU Pitié Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen
المصدر: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2018, 13, pp.annrheumdis--2017--212608. ⟨10.1136/annrheumdis-2017-212608⟩
Annals of the Rheumatic Diseases, Vol. 77, No 6 (2018) pp. 840-847
Annals of the Rheumatic Diseases, 2018, 13, pp.annrheumdis--2017--212608. ⟨10.1136/annrheumdis-2017-212608⟩
Annals of the rheumatic diseases, vol. 77, no. 6, pp. 840-847مصطلحات موضوعية: Adult, 0301 basic medicine, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Injections, Subcutaneous, Immunology, Disease, Severity of Illness Index, Drug Administration Schedule, General Biochemistry, Genetics and Molecular Biology, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Team4, Rheumatology, Prednisone, Internal medicine, medicine, Clinical endpoint, Humans, Immunology and Allergy, CRTI, Adverse effect, ComputingMilieux_MISCELLANEOUS, ddc:616, 030203 arthritis & rheumatology, Dose-Response Relationship, Drug, biology, business.industry, C-reactive protein, Interleukin-18, Interleukin, Middle Aged, Antirheumatic Agents/administration & dosage, Antirheumatic Agents/adverse effects, Antirheumatic Agents/therapeutic use, Biomarkers/blood, Female, Intercellular Signaling Peptides and Proteins/administration & dosage, Intercellular Signaling Peptides and Proteins/adverse effects, Intercellular Signaling Peptides and Proteins/therapeutic use, Interleukin-18/blood, Still's Disease, Adult-Onset/drug therapy, Still's Disease, Adult-Onset/immunology, Treatment Outcome, adult onset still’s disease, inflammation, juvenile idiopathic arthritis, 3. Good health, Clinical trial, Institutional repository, 030104 developmental biology, Antirheumatic Agents, biology.protein, Intercellular Signaling Peptides and Proteins, [SDV.IMM]Life Sciences [q-bio]/Immunology, business, Still's Disease, Adult-Onset, Biomarkers, medicine.drug
وصف الملف: application/pdf
-
8
المؤلفون: Christos G Papadopoulos, Paraskevi V. Voulgari, Alexandros A. Drosos, Spyros N Nikas, A N Georgiadis, Yannis Alamanos, Aliki I. Venetsanopoulou
المصدر: Annals of the Rheumatic Diseases. 65:257-260
مصطلحات موضوعية: Male, musculoskeletal diseases, medicine.medical_specialty, Concise Report, Immunology, Joints/physiopathology, Arthritis, Blood Sedimentation, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, C-Reactive Protein/analysis, Rheumatology, Internal medicine, medicine, Adalimumab, Health Status Indicators, Humans, Immunology and Allergy, skin and connective tissue diseases, Adverse effect, Aged, Antirheumatic Agents/*administration & dosage/adverse effects/therapeutic use, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Platelet Count, Tumor Necrosis Factor-alpha, business.industry, Antibodies, Monoclonal, Middle Aged, medicine.disease, Connective tissue disease, Infliximab, Surgery, C-Reactive Protein, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Monoclonal, Arthritis, Rheumatoid/*drug therapy/immunology/physiopathology, Antibodies, Monoclonal/*administration & dosage/adverse effects/therapeutic use, Female, Joints, business, medicine.drug
-
9
المؤلفون: Karim Sacre, Nathalie Costedoat-Chalumeau, Moez Jallouli, Olivier Fain, Véronique Le Guern, Amar Smail, Jean-Emmanuel Kahn, Thomas Papo, Lucile Musset, Laurent Perard, Philippe Lechat, Bouchra Asli, Gaëlle Leroux, Patrice Cacoub, Camille Francès, Nicolas Limal, Jacques Pourrat, Frédéric Lioté, Laurent Sailler, Jérôme Stirnemann, Marie-Laure Tanguy, Zahir Amoura, Hélène Desmurs-Clavel, Du Le Thi Huong Boutin, Judith Cohen-Bittan, Jean-Charles Piette, Jean-Sébastien Hulot, O. Aumaître, Felix Ackermann, Lionel Galicier
المساهمون: Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'immunologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de médecine interne, hôpital Gabriel-Montpied, CHU Clermont-Ferrand, Service de Dermatologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], CHU Saint-Antoine [APHP], Service de Médecine Interne, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 (UPD5), Service Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Laboratoire d'Immunologie (EA 2686), Université de Lille, Droit et Santé, Service de Néphrologie - Immunologie Clinique [Toulouse], CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse]-PRES Université de Toulouse, Hôpital Bichat - Claude Bernard, Service de médecine interne, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Jean Verdier [Bondy], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Biologie et thérapeutique des pathologies immunitaires (BTPI), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Service de biostatistiques et information médicale [CHU Pitié-Salpêtrière], Physiopathologie, génétique et pharmacologie du remodelage cardiovasculaire, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'immunologie [CHU Pitié-Salpétrière], Immunité et Infection, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR113-Université Pierre et Marie Curie - Paris 6 (UPMC), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Interne [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Jean Verdier [AP-HP], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Immunologie [CHU Pitié-Salpétrière], Université de Brest (UBO)-Université de Brest (UBO), Immunologie - Immunopathologie - Immunothérapeutique ( I3 ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Centre de Référence des microangiopathies thrombotiques ( CNR-MAT ), service d'hématologie-CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 ( UPD5 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 ( UPD7 ), Laboratoire d'Immunologie ( EA 2686 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Jean Verdier, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Biologie et thérapeutique des pathologies immunitaires ( BTPI ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), Institut des Maladies Neurodégénératives [Bordeaux] ( IMN ), Université de Bordeaux ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR14-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR113-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département de Médecine Interne et Pneumologie [Brest] ( DMIP - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-PRES Université de Toulouse, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM)
المصدر: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2013, 72 (11), pp.1786-92. ⟨10.1136/annrheumdis-2012-202322⟩
Annals of the Rheumatic Diseases, Vol. 72, No 11 (2013) pp. 1786-92
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2013, 72 (11), pp.1786-92. 〈10.1136/annrheumdis-2012-202322〉
Annals of the Rheumatic Diseases, 2013, 72 (11), pp.1786-92. ⟨10.1136/annrheumdis-2012-202322⟩مصطلحات موضوعية: Male, MESH: Antirheumatic Agents, MESH: Hydroxychloroquine, [SDV]Life Sciences [q-bio], MESH : Prospective Studies, MESH : Dose-Response Relationship, Drug, Gastroenterology, law.invention, MESH: Dose-Response Relationship, Drug, 0302 clinical medicine, Randomized controlled trial, Dosing schedules, law, immune system diseases, MESH: Drug Monitoring, Epidemiology, Clinical endpoint, Lupus Erythematosus, Systemic, MESH : Lupus Erythematosus, Systemic, Immunology and Allergy, MESH : Female, MESH: Double-Blind Method, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, skin and connective tissue diseases, MESH: Treatment Outcome, MESH: Middle Aged, MESH : Adult, Middle Aged, MESH : Antirheumatic Agents, MESH : Drug Monitoring, Connective tissue disease, 3. Good health, Treatment Outcome, Antirheumatic Agents, Female, France, Drug Monitoring, Drug Monitoring/methods, Hydroxychloroquine, medicine.drug, Adult, medicine.medical_specialty, MESH : Male, Immunology, MESH : Treatment Outcome, General Biochemistry, Genetics and Molecular Biology, Hydroxychloroquine/administration & dosage/blood, 03 medical and health sciences, Rheumatology, Pharmacokinetics, Double-Blind Method, Internal medicine, medicine, MESH : Double-Blind Method, Humans, MESH : Middle Aged, MESH: Lupus Erythematosus, Systemic, MESH : France, Antirheumatic Agents/administration & dosage/blood, 030203 arthritis & rheumatology, MESH: Humans, [ SDV ] Life Sciences [q-bio], Dose-Response Relationship, Drug, business.industry, MESH : Humans, MESH : Hydroxychloroquine, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, MESH: France, Lupus Erythematosus, Systemic/drug therapy, business, MESH: Female
-
10
المؤلفون: Mikkel Østergaard, Andrea Rubbert-Roth, Bernard Combe, Ferdinand C. Breedveld, Miho Murakami, Michael Trauner, Marieke Scholte-Voshaar, Angel Lanas, Maarten de Wit, Maurizio Cutolo, Gerd R Burmester, Paul Emery, Gabriele Valentini, Juan J. Gomez-Reino, Kevin L. Winthrop, Tore K Kvien, Gianfranco Ferraccioli, Karel Pavelka, Yoshiya Tanaka, Neil Betteridge, Norihiro Nishimoto, Naveed Sattar, Carlomaurizio Montecucco, Ernest Choy, Maxime Dougados, Winfried Graninger, Clifton O. Bingham, Graeme Jones, Désirée van der Heijde, Cem Gabay, Monika Schoels, Josef S Smolen, Allan Gibofsky, Emilio Martín-Mola, Vivian P. Bykerk
المساهمون: Smolen, J, Schoels, Mm, Nishimoto, N, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Betteridge, N, Bingham C., 3rd, Bykerk, V, Choy, Eh, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert Roth, A, Sattar, N, Scholte Voshaar, M, Tanaka, Y, Trauner, M, Valentini, Gabriele, Winthrop, Kl, de Wit, M, van der Heijde, D., Ethics, Law & Medical humanities, CCA - Innovative therapy
المصدر: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 482-92
Smolen, J S, Schoels, M M, Nishimoto, N, Breedveld, F C, Burmester, G R, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez-Reino, J J, Jones, G, Kvien, T K, Murakami, M, Betteridge, N, Bingham, C O, Bykerk, V, Choy, E H, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin-Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert-Roth, A, Sattar, N, Scholte-Voshaar, M, Tanaka, Y, Trauner, M, Valentini, G, Winthrop, K L, de Wit, M P T & van der Heijde, D 2013, ' Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions ', Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 482-492 . https://doi.org/10.1136/annrheumdis-2012-202469
Annals of the Rheumatic Diseases, 72(4), 482-492
Annals of the Rheumatic Diseases, 72(4), 482-492. BMJ Publishing Groupمصطلحات موضوعية: musculoskeletal diseases, Settore MED/16 - REUMATOLOGIA, Immunology, MEDLINE, Arthritis, Rheumatoid Arthritis, DMARDs (biologic), Bioinformatics, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, chemistry.chemical_compound, Tocilizumab, Rheumatology, medicine, Immunology and Allergy, Humans, Inflammation/drug therapy/immunology, Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects, Interleukin 6, skin and connective tissue diseases, ddc:616, Inflammation, biology, business.industry, Interleukin-6, Consensus Statement, medicine.disease, Connective tissue disease, Receptors, Interleukin-6, R1, Antirheumatic Agents/administration & dosage/adverse effects, Antirheumatic Agents, Arthritis, Rheumatoid/drug therapy/immunology, Treatment, chemistry, Interleukin-6/antagonists & inhibitors, Rheumatoid arthritis, Interleukin-6 receptor, Receptors, Interleukin-6/antagonists & inhibitors, biology.protein, Drug Monitoring, business, Drug Monitoring/methods
وصف الملف: application/pdf
